Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
418 studies found for:    PLG
Show Display Options
Rank Status Study
1 Completed A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency
Conditions: Type I Plasminogen Deficiency;   Hypoplasminogenemia
Intervention: Biological: Plasminogen (Human) Intravenous
2 Recruiting A Study of ProMetic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia
Condition: Hypoplasminogenemia
Intervention: Biological: Plasminogen (human) intravenous
3 Terminated
Has Results
Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema
Condition: Uveitis
Intervention: Drug: Microplasmin
4 Active, not recruiting Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients
Condition: Ligneous Conjunctivitis
Intervention: Biological: Human Plasminogen
5 Unknown  Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration
Condition: Macular Degeneration
Interventions: Drug: Microplasmin;   Drug: Placebo control
6 Completed Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion
Condition: Focal Vitreomacular Adhesion
Intervention: Drug: Microplasmin
7 Terminated Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT
Condition: Deep Vein Thrombosis
Intervention: Drug: microplasmin
8 Completed In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: recombinant tissue plasminogen activator;   Drug: captopril
9 Completed Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke
Condition: Stroke, Acute
Intervention: Drug: Microplasmin
10 Completed Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy
Conditions: Vitreomacular Traction Maculopathy;   Eye Diseases
Intervention: Drug: Microplasmin
11 Terminated Intra-arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery Occlusion
Condition: Stroke
Intervention: Drug: Microplasmin
12 Completed
Has Results
Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
Condition: Vitreomacular Adhesion
Interventions: Drug: Ocriplasmin 125µg;   Drug: Placebo
13 Completed
Has Results
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
Condition: Diabetic Macular Edema
Interventions: Drug: ocriplasmin;   Other: Sham injection
14 Completed
Has Results
Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.
Condition: Vitreomacular Adhesion
Interventions: Drug: 125 µg Ocriplasmin;   Drug: Placebo
15 Not yet recruiting Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
Condition: Plastic Bronchitis
Intervention: Drug: Inhaled tissue plasminogen activator (tPA)
16 Terminated Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion
Condition: Arterial Occlusive Diseases
Intervention: Drug: Microplasmin
17 Completed
Has Results
A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
Condition: Vitrectomy
Interventions: Drug: Ocriplasmin 25µg;   Drug: Ocriplasmin 75µg;   Drug: Ocriplasmin 125µg;   Drug: Placebo
18 Completed
Has Results
A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)
Condition: Vitreomacular Traction
Interventions: Drug: ocriplasmin;   Drug: Sham Comparator
19 Unknown  Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage
Conditions: Aneurysmal Subarachnoid Hemorrhage;   Intraventricular Hemorrhage
Interventions: Drug: Tissue Plasminogen Activator;   Drug: Placebo
20 Completed Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke.
Condition: Cerebrovascular Accident
Intervention: Genetic: Recombinant Human Plasminogen Activator (HTUPA)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.